solute carrier family 27 member 4Genealiases: ACSVL4 · FATP4 · IPS
Q-omics provides the consensus-scored SLC27A4 profile across patient tissues and cancer cell-line models. SLC27A4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SLC27A4 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, SLC27A4 protein abundance shows 24,252 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where SLC27A4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC27A4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC27A4 survival associations across molecular data types. SLC27A4 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC27A4 RNA expression–survival associations across cancer types. High SLC27A4 expression shows unfavorable associations in ACC, MESO, SKCM and LUAD, but favorable associations in SCLC and KIRP. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SLC27A4 RNA expression.
This table summarizes SLC27A4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC27A4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC27A4 shows lower tumor expression in KIRC and THCA and higher tumor expression in LUAD, LUSC, BLCA and UCEC. The KIRC box plot shows higher SLC27A4 RNA expression in normal versus tumor tissue (log2 FC = −1.261, t-test p < 0.001).
This table shows molecular features associated with SLC27A4 in patient tissues and cancer cell lines. In patient samples, SLC27A4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC27A4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
